46 results about "Anti arthritic" patented technology

The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic / analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages.

The invention relates to an Oral Delayed Immediate Release formulation comprising a compressed core containing one or more active substances surrounded with a coating, wherein release of active substance from the core is caused by rupture of the coating after a definite lag-time, said core comprising one or more immediate release carriers and having no substantial swelling properties upon exposure to gastrointestinal fluids. The invention further relates to formulations containing an Immediate Release formulation combined with one or more Oral Delayed Immediate Release formulations with different lag-times and to a method of preparing an Oral Delayed Immediate Release formulation.The Oral Delayed Immediate Release formulation may be used for the application of active substances whenever a certain lag-time before release is advantageous, such as in be the case of anti-asthmatics, anti-emetics, cardiotonics, vasodilators, anti-vertigo and anti-meniere compounds, anti-hypertensives, sedatives, anti-depressants, anti-anxiety compounds, cortico-steroids, general anti-inflammatory compounds, anti-inflammatory compounds for gastrointestinal use, anti-ulceratives, analgetics, anti-aritmics, anti-rheumatics, anti-arthritic compounds and anti-angina compounds.The Oral Delayed Immediate Release formulation may also be used for the application of biological active compounds such as proteins, peptides, enzymes, vaccines and oligonucleotides.

The present invention provides an oral formulation comprising ingredients extracted from Caulis Sinomenii, Radix Aconiti Lateralis Preparata, Radix Paeoniae Alba, Cortex Moutan, and Rhizoma Curcumae Longae. The formulation has anti-arthritic, anti-inflammatory and anti-nociceptive properties and is suitable for the treatment of arthritis, symptoms associated with arthritis and other similar conditions.

The present disclosure is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The disclosure also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic / analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages.

The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic / analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages.

The invention discloses a synthesis and medical application of pyrrolo-[2,1-f] [1,2,4] triazine mother nucleus compound. The compound belongs to a novel-structure compound. The synthesis method is high in operating safety, mild in reaction condition and suitable for industrial production. The activity and the selectivity of BTK kinase and the in-vitro proliferation activity of a leukemia cell line are test, it is verified that the compound has the selective and irreversible inhibition effect on the BTK kinase, and has the different-degree inhibition effect on leukemia cells. According to measurement, the compound also has the good anti-arthritic activity on a collagen-induced arthritis (rCIA) model. The pyrrolo-[2,1-f] [1,2,4] triazine mother nucleus compound can be used for preparing medicine for treating arthritis and leukemia.

The invention relates to a coumarin compound acidulated by glucal and application thereof. The compound has a structure showed in the right formular, wherein R is one of-H, -OH, -CH3, -OCH3, -NH2 or ester group; and R1, R2, R3 and R4 are one of -H, -OH, -CH3, -SH, -OCH3, -NH2 or glucal acid group. The coumarin compound acidulated by the glucal has the activities of resisting arthritic and tumor.

A benzophenone derivative represented by the following formula:whereinR1 represents, for example, an optionally substituted heterocyclic group, or a substituted phenyl group; Z represents, for example, an alkylene group; R2 represents, for example, a carboxyl group optionally protected with alkyl;R3 represents, for example, an optionally protected hydroxyl group; R4 represents, for example, an optionally substituted cycloalkyloxy group; and R5 represents, for example, a hydrogen atom,or a salt thereof has anti-arthritic activity, inhibits bone destruction caused by arthritis, and provides high safety and excellent pharmacokinetics and thus is useful as therapeutic agent for arthritis. These compounds have inhibitory effect on AP-1 activity and are useful as preventive or therapeutic agent for diseases in which excessive expression of AP-1 is involved.

The present invention provides an oral preparation comprising components extracted from Aconite chinensis, Aconite root, White peony root, Moutan bark and Curcuma longa. This preparation has anti-arthritic, anti-inflammatory and analgesic properties and is indicated for the treatment of arthritis, arthritis-related symptoms and other similar conditions.

The invention relates a group of compounds having formula (I) and their use as medicaments for non-steroidal analgesic analgesia, anti-arthritis, and protecting gastrointestinal tract mucous membrane. The invention also discloses the pharmaceutical compositions containing the compounds of formula (I), wherein R1, R2, R3 and X are defined in the specification.

The present invention is related to pharmaceutical composition essentially comprising herbal extract of Chaenomelis Fructus, Achyranthis Radix, Acanthopanax, Phlomidis Radix, Gentianae Radix, Clematidis Radix, and additionally comprising herbal extract selected from group consisting of Angelicae Radix, Cnidii Rhizoma, Gastrodiae Rhizoma, Safflower, Cinnamomi Cortex, Job's tear, Aurantii nobilis Pericapium, Ledebouriellae Radix, Lonicera japonica, Akebiae caulis, Caragana chamlagu, Licorice root, Notopterygium incisum, Persicae semen, Eucommia ulmoides, Atractylodes Rhizoma, Torilis japonica according to the need for the prevention and treatment of arthritic diseases and methods of using the above extracts and composition as potent anti-inflammatory and anti-arthritic agents.

The present invention relates to a novel oil extracted from the seeds of Momordica charantia L., for topical application to a body of mammal and used as anti-inflammatory, anti-arthritic, vasculodilatory and wound healing agent, said oil essentially comprising capric acid 0.7–1.2% by wt., lauric acid 0.6–1% by wt., palmitic acid 42–5.0% by wt., stearic acid 59–62% by wt., oleic acid 13–15% by wt., archid acid 3–5% by wt., linoleic acid 8–10% by wt., and other undetected minor acids 6–8% by wt.; and a process for producing such oil.

A compound inhibiting Hsp90 and a pharmaceutical composition including the same as an active ingredient are described, which compound is represented by formula 2 and suppresses the expression of Hsp90, inhibits the accumulation of HIF-1α, the Hsp90 client protein, and efficiently inhibits the activation of VEGF. The compound displays low cytotoxicity and can be effectively used as an active ingredient of an anti-cancer agent, a diabetic retinopathy treating agent, and an anti-arthritic agent.

The invention provides a novel herbal composition for treatment of arthritis and inflammation. The herbal composition comprises a therapeutically effective combination of extracts obtained from the plants Terminalia chebula, Pluchea lanceolata, Desmodium gangeticum, Vitex negunto and Zingiber officinale, optionally along with pharmaceutically acceptable additives. The invention further comprises methods of making the herbal composition and methods of use for the treatment of arthritis and inflammation.

The present invention relates to a novel oil extracted from the seeds of Momordica charantia L., for topical application to a body of mammal and used as anti-inflammatory, anti-arthritic, vasculodilatory and wound healing agent, said oil essentially comprising caprice acid 0.7-1.2% by wt., lauric acid 0.6-1% by wt., palmitic acid 4.2-5.0% by Wt,, stearic acid 59-62% by wt., oleic acid 13-15% by wt., archid acid 3-5 % by wt., linoleic acid 8-10% by wt., and other undetected minor acids 6-8 % by wt.; and a process for producing such oil.

Application of a quinonemethide triterpenoid or a pharmaceutically tolerable salt, solvate or anhydrate thereof in preparing medicine for the treatment of refractory rheumatoid arthritis, and application in medicine for inducing autophagy in a synovial fibroblast. Further a pharmaceutical composition includes an effective dose of a quinonemethide triterpenoid and an anti-arthritis compound. The quinonemethide triterpenoid is suitable to treat refractory rheumatoid arthritis (RA), in particular ABC-protein-dependent RA and apoptosis-deficient RA. The quinonemethide triterpenoid also possesses significant inhibitory effects on the growth of synovial fibroblasts, in particular modulating the calcium homeostasis in multidrug-resistant rheumatoid arthritis synovial fibroblasts.

The invention relates to the technical field of cells, and particularly discloses an application of mesenchymal stem cell-derived small extracellular vesicles to preparation of drugs for treating autoimmune diseases. The mesenchymal stem cell-derived small extracellular vesicles provided by the invention have the advantages of extremely low immunogenicity, small side effects, small rejection immune response, stability in a living body, natural homing and targeting properties and long residence time, the mesenchymal stem cell-derived small extracellular vesicles are made into drugs which have avery good treatment effect on rheumatoid arthritis, and arthritis can be effectively resisted.

The present invention relates to antibiotics, anti-inflammatory agents, antihyperlipidemia agents, antidiabetes agents and anticancer agents, of which medical treatment materials are extracted by hot water or organic solvent from 20-year (or older) perennial old platycodon (i.e., old platycodon) with various physiological effects, or selective mixture of these extracts and other allowable herbal medicines or herbal medicine extracts. The old platycodon extracts have further enhanced effects than conventional medicines or 2-4 year old common platycodon, in terms of antibiotic activity, lipid metabolism improving activity, blood glucose level lowering activity, inhibition activity against adhesion of cancer cells immunity increasing effect, anti-arthritis effect, etc.

The invention discloses composition containing kirenol and the application of the composition in medicament. The composition containing the kirenol is characterized by being formed by the kirenol and darutigenol, wherein the weight ratio of the kirenol and the darutigenol is 1 to (0.05 to 0.8). The composition containing the kirenol, disclosed by the invention, has a remarkable treating effect on gouty arthritis, rheumatic arthritis and rheumatoid arthritis, is used for preparing medicines which can be used for treating the gouty arthritis, the rheumatic arthritis and the rheumatoid arthritis, has the advantages of remarkable arthritis resisting function, clear chemical component and clear quality control index, is safe and effective, is clear in ingredient and provides a novel means for treating diseases such as arthritis and gout.

Chromium-three cation in combination with Phyllanthus emblica extract and Shilajit is useful in treating symptoms associated with osteoarthritis including reduction of inflammation and pain in a mammal, particularly a human or an animal. The combination shows significant reduction in overall pain levels and other pain measures in a canine model, and in human studies. Thus the composition is an anti-arthritic formulation that decreases pain and inflammation.

The invention belongs to the technical field of polymer chemistry, biomedical materials and pharmacy, and discloses a targeted controlled-release anti-arthritis medicinal preparation and a preparationmethod thereof. The pharmaceutical preparation is a drug-loaded micelle, the drug-loaded micelle is composed of a segmented copolymer PEG-PPS and tripterine, and the tripterine is loaded in the micelle formed by the segmented copolymer PEG-PPS. The preparation method comprises the following preparation steps: (1) dissolving 20-80 parts by mass of PEG-PPS and 1-10 parts by mass of tripterine in 5-10 parts by volume of tetrahydrofuran; and (2) under ultrasonic dispersion, adding the solution obtained in the step (1) into 50-100 parts by volume of water, carrying out vacuum distillation to remove tetrahydrofuran, and carrying out repeated ultrafiltration and sterile microporous filtration membrane filtration to obtain the anti-arthritis nano-drug preparation. The medicinal preparation disclosed by the invention is sensitive to rheumatoid arthritis inflammation, controllable release of the medicine can be realized, and joint synovitis and bone erosion can be obviously inhibited.

The invention discloses a diclofenac-glycine-resveratrol conjugate, a preparation method and an application. The conjugate is formed by coupling glycine serving as a linking arm with diclofenac and resveratrol respectively; diclofenac and glycine are linked by an amido bond; a diclofenac-glycine conjugate is linked with resveratrol by multiple sites of ester bonds. Due to introduction of glycine,the solubility of the conjugate is increased, due to introduction of diclofenac and resveratrol, the anti-arthritis effect of the conjugate is significantly enhanced, adverse reactions are reduced, and safety is higher. The synthesis method of the conjugate is simple and suitable for industrial production.

The present invention relates to compositions comprising one or more connective tissue derived polypeptides having a molecular weight of less than 30,000 Da that are capable of tolerising individuals to antigenic components of cartilage and prevent the appearance of and / or treat symptoms of arthritis and other musculoskeletal degenerative conditions. The present invention provides methods for recovering polypeptides having a molecular weight of less than 30,000 Da from connective tissue and having anti-arthritic or anti-inflammatory activity. The present invention further relates to compositions comprising a polypeptide containing an NC4 domain of collagen type IX alpha 1 chain or fragment thereof, having a molecular weight of less than 30,000 Da, where the polypeptide is capable of tolerising individuals to antigenic components of cartilage, preventing the appearance of arthritic symptoms, and / or treating the symptoms of arthritis.

The invention discloses a diclofenac-glycine-resveratrol conjugate, a preparation method and an application. The conjugate uses glycine as a connecting arm, and is respectively coupled with diclofenac and resveratrol; the diclofenac and glycine are connected through an amide bond; and the diclofenac-glycine conjugate is connected with resveratrol at multiple sites through an ester bond. Due to the introduction of glycine, the solubility of the conjugate increases, and the introduction of diclofenac and resveratrol significantly enhances the anti-arthritis effect of the conjugate, reduces adverse reactions, and has higher safety; the synthesis method of the conjugate is simple and suitable for industrialization Production.

The invention relates to a novel anti-inflammatory drug, in particular to TLR4 / MD2 inhibitors, i.e., compounds N-substituted-4-(5-dimethylamino-1-naphthalene)sulfonyl oxy benzoxazole-2-one and application thereof in anti-inflammatory drugs. The compounds provided by the invention can significantly inhibit the release of NO and inflammatory cytokines IL-1 beta and IL-6 of lipopolysaccharide (LPS) induced mouse macrophages, can remarkably inhibit the expression of TLR4, MYD88 and IRAK4 in a TLR4 inflammatory signaling pathway, and prevents NF-k kappa B from entering nucleus, thereby inhibiting the expression of inflammatory effector molecules COX2 and IL-6 and further exerting anti-inflammatory activity; the compounds can significantly inhibit xylene-induced ear swelling in mice, and has higher efficacy compared with the clinically commonly used anti-inflammatory drug-celecoxib at the same dose; the compounds can obviously inhibit the release of mouse lung tissue inflammatory cytokines induced by LPS; the compounds can significantly inhibit the joint swelling and expression of inflammatory factors thereof in rats with collagen-induced arthritis, and is better in curative effect compared with the clinically commonly used anti-arthritic drug-phenylbutazone; the maximum oral tolerance is 5000 mg / kg, and the compounds are basically non-toxic compounds.

The invention provides an application of pericarpium citri reticulatae essential oil to preparation of products for preventing or treating arthritis. Research results show that a pericarpium citri reticulatae essential oil component can relieve CFA-induced rheumatoid arthritis of rats and can effectively relieve joint tissue damage caused by CFA; and the pericarpium citri reticulatae essential oilcan inhibit the lesion degree of arthritis by inhibiting activity expression of tumor necrosis factors TNF-alpha and COX-2, and control the joint arthritis reaction, so that the pain of a patient caused by the arthritis is relieved to the greatest extent, and a new choice is provided for developing novel anti-arthritis medicines.

The invention relates to a novel anti-inflammatory drug, in particular to TLR4 / MD2 inhibitors, i.e., compounds N-substituted-4-(5-dimethylamino-1-naphthalene)sulfonyl oxy benzoxazole-2-one and application thereof in anti-inflammatory drugs. The compounds provided by the invention can significantly inhibit the release of NO and inflammatory cytokines IL-1 beta and IL-6 of lipopolysaccharide (LPS) induced mouse macrophages, can remarkably inhibit the expression of TLR4, MYD88 and IRAK4 in a TLR4 inflammatory signaling pathway, and prevents NF-k kappa B from entering nucleus, thereby inhibiting the expression of inflammatory effector molecules COX2 and IL-6 and further exerting anti-inflammatory activity; the compounds can significantly inhibit xylene-induced ear swelling in mice, and has higher efficacy compared with the clinically commonly used anti-inflammatory drug-celecoxib at the same dose; the compounds can obviously inhibit the release of mouse lung tissue inflammatory cytokines induced by LPS; the compounds can significantly inhibit the joint swelling and expression of inflammatory factors thereof in rats with collagen-induced arthritis, and is better in curative effect compared with the clinically commonly used anti-arthritic drug-phenylbutazone; the maximum oral tolerance is 5000 mg / kg, and the compounds are basically non-toxic compounds.

A compound inhibiting Hsp90 and a pharmaceutical composition including the same as an active ingredient are described, which compound is represented by formula 2 and suppresses the expression of Hsp90, inhibits the accumulation of HIF-1α, the Hsp90 client protein, and efficiently inhibits the activation of VEGF. The compound displays low cytotoxicity and can be effectively used as an active ingredient of an anti-cancer agent, a diabetic retinopathy treating agent, and an anti-arthritic agent.